Completed PHASE2 INTERVENTIONAL NCT00266006

Factor VIIa in Acute Intracerebral Haemorrhage

Safety of Eptacog Alfa (Activated) (Genetical Recombination) on Adverse Events and Serious Adverse Events in Patients With Acute Intracerebral Haemorrhage.

Sponsor: Novo Nordisk A/S

Conditions Acquired Bleeding Disorder Intracerebral Haemorrhage

Interventions eptacog alfa (activated)

Updated 5 times since 2017 Last updated: Nov 16, 2016 Started: Jan 31, 2006 Primary completion: Apr 30, 2007 Completion: Apr 30, 2007

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00266006, this PHASE2 trial focuses on Acquired Bleeding Disorder and Intracerebral Haemorrhage and remains completed. Sponsored by Novo Nordisk A/S, it has been updated 5 times since 2006, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Jan 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Novo Nordisk A/S

Data source: Novo Nordisk A/S

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Tokyo, Japan